Jubilant Pharmova Q1 FY27 Financial Performance Review: Revenue Growth, Declining Profits

Jubilant Pharmova, a leading pharmaceutical company, saw its shares decline by 6% after the company reported a 45% year-over-year (YoY) decline in profits for the first quarter (Q1) of the fiscal year 2027 (FY27). The decline in profits was attributed to lower operating profitability and an increase in depreciation for Line 3 in Spokane.

Pharmova’s Q1 FY27 Financial Performance

The company’s revenue increased by 17% YoY to Rs 2,229 crore in Q1 FY27, driven by strong performance across all business segments, with CDMO Sterile Injectables delivering particularly robust growth. The total income jumped 18% to Rs 2,249 crore against Rs 1,913 crore in Q1 FY26.

The other income for Q1 FY27 includes grant income of Rs 5.6 crore for Line 3, which is expected to continue for more than 20 years and up to 30 years.

Segmental Business Performance

Jubilant Pharmova’s segmental business performance was mixed in Q1 FY27. The Radiopharma segment reported a 19% increase in revenue to Rs 322 crore, while EBITDA margins decreased YoY due to unavailability of certain SPECT products.

Market Impact and Details

• The company’s shares declined by 6% after the Q1 FY27 earnings announcement.
• The decline in profits was attributed to lower operating profitability and an increase in depreciation for Line 3 in Spokane.
• The company’s revenue increased by 17% YoY to Rs 2,229 crore in Q1 FY27.
• The total income jumped 18% to Rs 2,249 crore against Rs 1,913 crore in Q1 FY26.
• The company’s EBITDA decreased YoY, particularly due to unavailability of SPECT products in Radiopharmaceuticals & negligible third-party revenues and higher operating expenses including incremental remediation cost at CMO Montreal.

Key Takeaways

• Jubilant Pharmova’s shares declined by 6% after the Q1 FY27 earnings announcement.
• The company’s revenue increased by 17% YoY to Rs 2,229 crore in Q1 FY27.
• The company’s EBITDA decreased YoY, particularly due to unavailability of SPECT products in Radiopharmaceuticals & negligible third-party revenues and higher operating expenses including incremental remediation cost at CMO Montreal.

FAQs

What was the reason for the decline in Jubilant Pharmova’s profits in Q1 FY27?

The decline in profits was attributed to lower operating profitability and an increase in depreciation for Line 3 in Spokane.

What was the impact of the unavailability of SPECT products on Jubilant Pharmova’s EBITDA margins?

The unavailability of SPECT products led to a decrease in EBITDA margins in the Radiopharma segment.

What are the company’s expectations for the future?

Jubilant Pharmova expects its revenue to reach 2x from FY24 to FY30, with EBITDA margins expected to be between 23% to 25% by FY30.

Conclusion

Jubilant Pharmova’s Q1 FY27 financial performance was mixed, with revenue increasing by 17% YoY to Rs 2,229 crore, but EBITDA decreasing YoY due to various factors. The company’s shares declined by 6% after the earnings announcement. As the company continues to navigate the challenges in the pharmaceutical industry, investors will be closely watching its future performance. With its strong revenue growth and expectations for future expansion, Jubilant Pharmova remains a key player in the industry.